Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
LJ Nannini, TJ Lasserson… - Cochrane Database of …, 2012 - cochranelibrary.com
Background Both inhaled steroids (ICS) and long‐acting beta 2‐agonists (LABA) are used in
the management of chronic obstructive pulmonary disease (COPD). This updated review …
the management of chronic obstructive pulmonary disease (COPD). This updated review …
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis
M Cazzola, P Rogliani, L Calzetta… - European Respiratory …, 2018 - Eur Respiratory Soc
We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
L Calzetta, P Rogliani, J Ora, E Puxeddu… - European …, 2017 - Eur Respiratory Soc
When there are no randomised clinical trials directly comparing all relevant treatment
options, an indirect treatment comparison via meta-analysis of the available clinical …
options, an indirect treatment comparison via meta-analysis of the available clinical …
The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a …
CC Lai, CH Chen, CYH Lin, CY Wang… - International journal of …, 2019 - Taylor & Francis
Background This study aims to compare the effects of single inhaler triple therapy comprised
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …
of inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and long-acting …
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
LJ Nannini, P Poole, SJ Milan… - Cochrane Database …, 2013 - cochranelibrary.com
Background Both long‐acting beta 2‐agonists (LABA) and inhaled corticosteroids (ICS)
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …
have been recommended in guidelines for the treatment of chronic obstructive pulmonary …
Triple therapy in COPD: what we know and what we don't
PMA Calverley, H Magnussen… - COPD: Journal of …, 2017 - Taylor & Francis
Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed …
Despite several long-acting β 2-adrenoceptor agonist (LABA)/long-acting muscarinic
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …
antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved for the treatment …
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
P Rogliani, L Calzetta, F Braido, M Cazzola… - … Journal of Chronic …, 2018 - Taylor & Francis
Objectives The aim of this study was to assess the current evidence for long-acting β2-
agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) …
agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) …
相关搜索
- acting bronchodilators meta analysis
- acting bronchodilators combination therapy
- combination therapy meta analysis
- laba ics meta analysis
- lama monotherapy meta analysis
- duration of treatment meta analysis
- bronchodilators alone meta analysis
- bronchodilator therapy meta analysis
- bronchodilators alone combination therapy